Total Payments
$17,801
2019 Payments
$28.67
Companies
2
Transactions
26
Payment Breakdown by Category
Research$14,581 (81.9%)
Consulting$3,191 (17.9%)
Food & Beverage$28.67 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14,581 | 24 | 81.9% |
| Consulting Fee | $3,191 | 1 | 17.9% |
| Food and Beverage | $28.67 | 1 | 0.2% |
Payments by Type
Research
$14,581
24 transactions
General
$3,220
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $17,772 | 25 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $28.67 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $28.67 | 1 | Novartis Pharmaceuticals Corporation ($28.67) |
| 2017 | $17,772 | 25 | GENZYME CORPORATION ($17,772) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/07/2019 | Novartis Pharmaceuticals Corporation | MAYZENT (Drug) | Food and Beverage | In-kind items and services | $28.67 | General |
| Category: NEUROSCIENCE | ||||||
| 12/31/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $1,039.29 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of • Category: MULTIPLE SCLEROSIS | ||||||
| 12/31/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $909.38 | Research |
| Study: A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis • Category: MULTIPLE SCLEROSIS | ||||||
| 12/31/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $666.87 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of • Category: MULTIPLE SCLEROSIS | ||||||
| 12/31/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $458.31 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of • Category: MULTIPLE SCLEROSIS | ||||||
| 12/31/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $356.47 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of • Category: MULTIPLE SCLEROSIS | ||||||
| 09/01/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $545.63 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of • Category: MULTIPLE SCLEROSIS | ||||||
| 08/24/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $458.31 | Research |
| Study: A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis • Category: MULTIPLE SCLEROSIS | ||||||
| 07/31/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $401.03 | Research |
| Study: A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis • Category: MULTIPLE SCLEROSIS | ||||||
| 06/26/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $808.33 | Research |
| Study: An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 m • Category: MULTIPLE SCLEROSIS | ||||||
| 06/24/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $401.60 | Research |
| Study: A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis • Category: MULTIPLE SCLEROSIS | ||||||
| 06/23/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $488.53 | Research |
| Study: TOWER - A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis, • Category: MULTIPLE SCLEROSIS | ||||||
| 06/08/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $1,130.22 | Research |
| Study: A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis • Category: MULTIPLE SCLEROSIS | ||||||
| 05/31/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $534.70 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of • Category: MULTIPLE SCLEROSIS | ||||||
| 05/31/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $458.31 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of • Category: MULTIPLE SCLEROSIS | ||||||
| 05/30/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $320.82 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of • Category: MULTIPLE SCLEROSIS | ||||||
| 05/25/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $909.38 | Research |
| Study: A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis • Category: MULTIPLE SCLEROSIS | ||||||
| 05/24/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $1,212.50 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of • Category: MULTIPLE SCLEROSIS | ||||||
| 05/24/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $727.50 | Research |
| Study: An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 m • Category: MULTIPLE SCLEROSIS | ||||||
| 05/10/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $500.15 | Research |
| Study: A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis • Category: MULTIPLE SCLEROSIS | ||||||
| 04/28/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $666.87 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of • Category: MULTIPLE SCLEROSIS | ||||||
| 04/28/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $571.61 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of • Category: MULTIPLE SCLEROSIS | ||||||
| 04/28/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $400.12 | Research |
| Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of • Category: MULTIPLE SCLEROSIS | ||||||
| 04/25/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | Consulting Fee | In-kind items and services | $3,191.13 | General |
| Category: MULTIPLE SCLEROSIS | ||||||
| 04/11/2017 | GENZYME CORPORATION | AUBAGIO (Drug) | — | In-kind items and services | $431.98 | Research |
| Study: TOPIC - An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily • Category: MULTIPLE SCLEROSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of | GENZYME CORPORATION | $7,415 | 13 |
| A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis | GENZYME CORPORATION | $4,710 | 7 |
| An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily and 14 m | GENZYME CORPORATION | $1,536 | 2 |
| TOWER - A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis, | GENZYME CORPORATION | $488.53 | 1 |
| TOPIC - An International, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment With Teriflunomide 7 mg Once Daily | GENZYME CORPORATION | $431.98 | 1 |
About Aaron Miller
Aaron Miller is a Pediatrics healthcare provider based in Bronx, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/28/2006. The National Provider Identifier (NPI) number assigned to this provider is 1730245754.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Aaron Miller has received a total of $17,801 in payments from pharmaceutical and medical device companies, with $28.67 received in 2019. These payments were reported across 26 transactions from 2 companies. The most common payment nature is "" ($14,581).
Ad
Practice Information
- Specialty Pediatrics
- Location Bronx, NY
- Active Since 12/28/2006
- Last Updated 07/08/2007
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1730245754
Products in Payments
- AUBAGIO (Drug) $17,772
- MAYZENT (Drug) $28.67
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Bronx
Philip Ozuah, Md, MD
Pediatrics — Payments: $1.0M
Pediatrics $1.0M
Dr. Giancarlo Guido, M.d, M.D
Pediatrics — Payments: $107,731
Pediatrics $107,731
Dr. Bryan Rudolph, Md, Mph, MD, MPH
Pediatrics — Payments: $104,918
Pediatrics $104,918
Jennifer Davila, Md, MD
Pediatrics — Payments: $95,463
Pediatrics $95,463
Acklema Mohammad, Md, MD
Pediatrics — Payments: $37,568
Pediatrics $37,568
Solomon Moshe, Md, MD
Pediatrics — Payments: $26,472
Pediatrics $26,472